
June 16 (Reuters) - Cancer diagnostic firm Caris Life Sciences said on Monday it was targeting a valuation of $5.67 billion in its U.S. initial public offering, after raising its proposed price range.
The Irving, Texas-based company is marketing the IPO at a price range between $19 and $20 apiece, according to a regulatory filing. It is seeking up to $470.6 million.
BofA Securities, J.P. Morgan, Goldman Sachs and Citigroup are the lead underwriters.
Caris will start trading on the Nasdaq on Wednesday under the symbol 'CAI'.